Aggregation‐induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image‐guided siRNA Therapy of Hepatocellular Carcinoma

Yu‐chen Hou,Chao Zhang,Zi‐jie Zhang,Lei Xia,Ke‐qiang Rao,Li‐hong Gu,Yi‐chi Wu,Zi‐cheng Lv,Hao‐xiang Wu,Xiao‐lei Zuo,Fan Li,Hao Feng,Qiang Xia
DOI: https://doi.org/10.1002/adhm.202200579
IF: 10
2022-06-30
Advanced Healthcare Materials
Abstract:Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and remains a global health challenge. Small interfering RNA (siRNA) is a promising therapeutic modality that blocks multiple disease‐causing genes without impairing cell structures. However, siRNA therapeutics still have off‐target proportion and lack effective quantitative analysis method in vivo. Thus, a novel theragnostic nanoparticle with dual‐mode imaging was synthesized for targeted and image‐guided siRNA therapy of HCC. Survivin siRNA was carried by Poly ethylenimine (PEI) and interacted with T7‐AIE/Gd NPs, which were self‐assembled of DSPE‐PEG‐DTPA(Gd), DSPE‐PEG‐Mal, DSPE‐PEG‐PEI, and TPE. The resulting theragnostic nanoparticles exhibited lower toxicity and high therapeutic effect, and excellent T1‐weighted MRI and AIE imaging performance. Moreover, in vivo MRI and AIE imaging indicate that this kind of theragnostic nanoparticles rapidly accumulated in the tumor due to active targeting and enhanced permeability and retention (EPR) effects. Sur@T7‐AIE‐Gd suppresses HCC tumor growth by inducing autophagy and destabilize DNA integrity in tumor cells. The results suggested that T7‐AIE‐Gd nanoparticles carrying Survivin siRNA with dual‐mode imaging characteristics were promising for targeted and image‐guided siRNA therapy of hepatocellular carcinoma. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?